Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Apr;39(4):868–871. doi: 10.1128/aac.39.4.868

In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp.

H M Wardle 1, D Law 1, C B Moore 1, C Mason 1, D W Denning 1
PMCID: PMC162644  PMID: 7785986

Abstract

We compared the in vitro activity of a new triazole, D0870, with those of fluconazole, itraconazole, and ketoconazole against 41 clinical isolates of fluconazole-resistant Candida belonging to nine different species. The 50% inhibitory concentrations (IC50s) were determined by a microdilution method with morpholinopropanesulfonic acid (MOPS)-buffered RPMI medium and an inoculum of approximately 10(4) yeasts per ml. After incubation for 48 h at 37 degrees C the optical density at 550 nm was measured. The IC50 was the lowest drug concentration which reduced the optical density at 550 nm by > or = 50% compared with that for a drug-free control. D0870 had significant activity against many of the isolates. Its activity was comparable to that of ketoconazole, slightly superior to that of itraconazole, and markedly superior to that of fluconazole against Candida albicans. Against Candida glabrata, Candida krusei, and Candida inconspicua, it had activity similar to those of itraconazole and ketoconazole but had activity superior to that of fluconazole. D0870 IC50s for some isolates were increased. This may be due to cross-resistance mechanisms because the IC50s of both itraconazole and ketoconazole for these isolates were often high. When IC50s and IC80s were compared there was a marked organism and drug variation. With C. glabrata much higher endpoints for itraconazole were observed when an IC80 endpoint was used. For C. albicans there was also a significant shift upward in endpoints for itraconazole and ketoconazole. Values were changed little when IC50 and IC80 endpoints of D0870 were compared. For 35 of 41 isolates tested the D0870 IC50 was less than the 2.5-mg/liter breakpoint threshold proposed previously. Therefore, D0870 may be a useful agent for the therapy of infections caused by fluconazole-resistant Candida spp.

Full Text

The Full Text of this article is available as a PDF (188.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baily G. G., Perry F. M., Denning D. W., Mandal B. K. Fluconazole-resistant candidosis in an HIV cohort. AIDS. 1994 Jun;8(6):787–792. doi: 10.1097/00002030-199406000-00010. [DOI] [PubMed] [Google Scholar]
  2. Boken D. J., Swindells S., Rinaldi M. G. Fluconazole-resistant Candida albicans. Clin Infect Dis. 1993 Dec;17(6):1018–1021. doi: 10.1093/clinids/17.6.1018. [DOI] [PubMed] [Google Scholar]
  3. Donnelly J. P. Describing and comparing in-vitro antimicrobial activity by the box-plot technique. J Antimicrob Chemother. 1992 Nov;30(5):713–719. doi: 10.1093/jac/30.5.713. [DOI] [PubMed] [Google Scholar]
  4. Fan-Havard P., Capano D., Smith S. M., Mangia A., Eng R. H. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991 Nov;35(11):2302–2305. doi: 10.1128/aac.35.11.2302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fox R., Neal K. R., Leen C. L., Ellis M. E., Mandal B. K. Fluconazole resistant candida in AIDS. J Infect. 1991 Mar;22(2):201–204. doi: 10.1016/0163-4453(91)91767-r. [DOI] [PubMed] [Google Scholar]
  6. Galgiani J. N. Susceptibility testing of fungi: current status of the standardization process. Antimicrob Agents Chemother. 1993 Dec;37(12):2517–2521. doi: 10.1128/aac.37.12.2517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hay R. J. Overview of the treatment of disseminated fungal infections. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):17–25. doi: 10.1093/jac/28.suppl_b.17. [DOI] [PubMed] [Google Scholar]
  8. Hitchcock C. A., Barrett-Bee K. J., Russell N. J. Inhibition of 14 alpha-sterol demethylase activity in Candida albicans Darlington does not correlate with resistance to azole. J Med Vet Mycol. 1987 Oct;25(5):329–333. [PubMed] [Google Scholar]
  9. Hitchcock C. A., Barrett-Bee K. J., Russell N. J. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J Gen Microbiol. 1986 Sep;132(9):2421–2431. doi: 10.1099/00221287-132-9-2421. [DOI] [PubMed] [Google Scholar]
  10. Hitchcock C. A., Pye G. W., Troke P. F., Johnson E. M., Warnock D. W. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother. 1993 Sep;37(9):1962–1965. doi: 10.1128/aac.37.9.1962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hitchcock C. A. Resistance of Candida albicans to azole antifungal agents. Biochem Soc Trans. 1993 Nov;21(4):1039–1047. doi: 10.1042/bst0211039. [DOI] [PubMed] [Google Scholar]
  12. Hitchcock C. A., Russell N. J., Barrett-Bee K. J. Sterols in Candida albicans mutants resistant to polyene or azole antifungals, and of a double mutant C. albicans 6.4. Crit Rev Microbiol. 1987;15(1):111–115. doi: 10.3109/10408418709104454. [DOI] [PubMed] [Google Scholar]
  13. Kitchen V. S., Savage M., Harris J. R. Candida albicans resistance in AIDS. J Infect. 1991 Mar;22(2):204–205. doi: 10.1016/0163-4453(91)91789-z. [DOI] [PubMed] [Google Scholar]
  14. Law D., Moore C. B., Wardle H. M., Ganguli L. A., Keaney M. G., Denning D. W. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother. 1994 Nov;34(5):659–668. doi: 10.1093/jac/34.5.659. [DOI] [PubMed] [Google Scholar]
  15. Moore C. B., Law D., Denning D. W. In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp. J Antimicrob Chemother. 1993 Dec;32(6):831–836. doi: 10.1093/jac/32.6.831. [DOI] [PubMed] [Google Scholar]
  16. Ng T. T., Denning D. W. Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect. 1993 Mar;26(2):117–125. doi: 10.1016/0163-4453(93)92707-4. [DOI] [PubMed] [Google Scholar]
  17. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  18. Peng T., Galgiani J. N. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother. 1993 Oct;37(10):2126–2131. doi: 10.1128/aac.37.10.2126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pfaller M. A., Bale M., Buschelman B., Lancaster M., Espinel-Ingroff A., Rex J. H., Rinaldi M. G. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol. 1994 Jul;32(7):1650–1653. doi: 10.1128/jcm.32.7.1650-1653.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pfaller M. A., Dupont B., Kobayashi G. S., Müller J., Rinaldi M. G., Espinel-Ingroff A., Shadomy S., Troke P. F., Walsh T. J., Warnock D. W. Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother. 1992 Sep;36(9):1805–1809. doi: 10.1128/aac.36.9.1805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ryley J. F., Wilson R. G., Barrett-Bee K. J. Azole resistance in Candida albicans. Sabouraudia. 1984;22(1):53–63. [PubMed] [Google Scholar]
  22. Smith D., Boag F., Midgley J., Gazzard B. Fluconazole resistant candida in AIDS. J Infect. 1991 Nov;23(3):345–346. doi: 10.1016/0163-4453(91)93584-y. [DOI] [PubMed] [Google Scholar]
  23. Smith K. J., Warnock D. W., Kennedy C. T., Johnson E. M., Hopwood V., Van Cutsem J., Vanden Bossche H. Azole resistance in Candida albicans. J Med Vet Mycol. 1986 Apr;24(2):133–144. [PubMed] [Google Scholar]
  24. St Georgiev V. Fungal infections and the search for novel antifungal agents. Opening remarks. Ann N Y Acad Sci. 1988;544:1–3. doi: 10.1111/j.1749-6632.1988.tb40384.x. [DOI] [PubMed] [Google Scholar]
  25. Williamson D. F., Parker R. A., Kendrick J. S. The box plot: a simple visual method to interpret data. Ann Intern Med. 1989 Jun 1;110(11):916–921. doi: 10.7326/0003-4819-110-11-916. [DOI] [PubMed] [Google Scholar]
  26. Willocks L., Leen C. L., Brettle R. P., Urquhart D., Russell T. B., Milne L. J. Fluconazole resistance in AIDS patients. J Antimicrob Chemother. 1991 Dec;28(6):937–939. doi: 10.1093/jac/28.6.937. [DOI] [PubMed] [Google Scholar]
  27. Yamada H., Tsuda T., Watanabe T., Ohashi M., Murakami K., Mochizuki H. In vitro and in vivo antifungal activities of D0870, a new triazole agent. Antimicrob Agents Chemother. 1993 Nov;37(11):2412–2417. doi: 10.1128/aac.37.11.2412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. vanden Bossche H., Marichal P., Odds F. C., Le Jeune L., Coene M. C. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1992 Dec;36(12):2602–2610. doi: 10.1128/aac.36.12.2602. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES